The INVOS™ Regional Oximetry Strategic Partner Solution is a cerebral/somatic oximeter that non-invasively measures regional oxygen saturation (rSO₂) at the capillary bed to detect site-specific adequacy of tissue perfusion in patients of all ages and weights:

- Unique sensor designs optimized for adult, pediatric and infant/neonatal patients
- Simultaneous, two or four channel cerebral/somatic monitoring capability
- Ability to monitor any cerebral/somatic site

**How INVOS™ Cerebral/Somatic Oximetry works**

Using a proprietary algorithm, the INVOS™ Regional Oximetry Strategic Partner Solution provides clinicians with immediate, actionable information to optimize patient care:

- The appropriately sized sensor is placed directly on the desired monitoring site (such as the forehead for cerebral oximetry)
- Two specific wavelengths of near-infrared light are used to determine the oxygen-hemoglobin saturation in the tissue beneath the sensor
- Two detectors (shallow and deep) are uniquely spaced to enable suppression of superficial tissue
- This provides an accurate measurement of site-specific tissue oxygenation
The benefits of detecting cerebral perfusion with INVOS™ technology

Randomized, controlled clinical studies have demonstrated that cerebral oxygenation monitoring with INVOS™ technology helps clinicians intervene sooner, avoid significant desaturations and reduce a wide range of adverse patient outcomes, such as:

- Major organ morbidity or mortality
- Post-operative cognitive decline
- Prolonged time on mechanical ventilation
- Adverse surgical events
- ICU length of stay
- Hospital length of stay

Society of Thoracic Surgeons Adult Cardiac Surgery Database Query: In 23% of adult cardiovascular surgery procedures using cerebral oximetry monitoring, the monitoring information provided the first indication of a technical problem or physiological change that could lead to an adverse outcome.

Setting the standard in regional oximetry

Only INVOS™ technology has been demonstrated through rigorous, peer-reviewed clinical research to improve patient outcomes by facilitating timely interventions under normal practice conditions:

- Only regional saturation oximeter with RCT-level evidence demonstrating a positive impact on outcomes
- Findings in three published randomized controlled trials has established the clinical value of the INVOS rSO₂ measurement
- Only claim for improved outcomes after surgery supported by the FDA
- Only system specifically used in 600+ published, peer-reviewed articles (internal data on file at Covidien)
- The clinical reference standard in regional oximetry

<table>
<thead>
<tr>
<th></th>
<th>INVOS™</th>
<th>Competitor 1</th>
<th>Competitor 2</th>
<th>Competitor 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Articles, Abstracts, and Posters</td>
<td>785+</td>
<td>≈100</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Published and Peer-Reviewed Articles</td>
<td>600+</td>
<td>16+</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Outcome Correlation (peer reviewed)</td>
<td>30+</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

7. FDA 510(k) K082327.